Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Inclusion Criteria:

• Male or female patients aged 18-75
• diagnosed as portal hypertension by contrast-enhanced computed tomography
• diagnosed as JAK2 positive

Exclusion Criteria:

• not had portal contrast-enhanced computed tomography
• not had JAK2 mutation test
• other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Patients with gastric and/or esophageal varices and JAK2 mutation.